In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Trimeris Inc.

Division of Alexion Pharmaceuticals Inc.

Latest From Trimeris Inc.

HIV/AIDS Drugs Moved Off Specialty Tier In Aetna Exchange Plans

Most HIV/AIDS drugs will be moved from the specialty tier to the generic or non-preferred brand tiers in the individual plans offered by Aetna and its Coventry subsidiary, beginning June 1.

BioPharmaceutical United States

Humana Lowers HIV Drug Cost Sharing

Humana joins Coventry and Cigna in agreeing to lower cost sharing for HIV drugs in health plans offered in Florida.

BioPharmaceutical United States

HIV Drug Copay Case Spotlights Discriminatory Formulary Issue In Exchange Plans

Cigna agrees to cap cost-sharing for some HIV/AIDS drugs at $200 in its exchange plans in Florida as a result of a consent agreement with state regulators. AIDS activists had filed a complaint with HHS alleging Cigna and three other insurers in the state were discriminating against patients with their high copays for HIV/AIDS drugs.

BioPharmaceutical United States

Stockwatch: Salutary lessons in drug commercialization

Last week, personalized cancer vaccine company Dendreon appeared to be in terminal decline as it struggles with low sales of its expensive product for prostate cancer, Provenge (sipuleucel-T), in the face of cheaper, more easily administered and more efficacious competition, and also with a large debt mountain. Dendreon is a rare and, you would think, salutary event in life science investing.

Infectious Diseases Cancer
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Infectious & Viral Diseases
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Alexion Pharmaceuticals Inc.
  • Senior Management
  • Martin A Mattingly, CEO
    James R Thomas, CFO
  • Contact Info
  • Trimeris Inc.
    Phone: (919) 806-4682
    2530 Meridian Pkwy., 2nd Fl.
    Durham, NC 27713